Photo of Morgan Cheatham, Vice President

Morgan Cheatham

Vice President


Morgan Cheatham is a vice president with Bessemer Venture Partners in the NYC office where he focuses on healthcare and life sciences investments from seed to growth stages. He specializes across the value chain spanning software, therapeutics, services, and diagnostics, to improve patient care from bench to bedside and leads investing efforts in biomedical artificial intelligence.

Select investments in his portfolio include Abridge, Hinge Health, Seismic Therapeutic, Headspace Health (fka Ginger), Subtle Medical, Turquoise Health, Productboard, Plenful, Groups Recover Together, Ansible Health, US Health Partners, and FOLX Health, where he serves on the board and previously served as Interim CEO. He was awarded Forbes 30U30 for Venture Capital and the National Venture Capital Association Rising Star Award (2023).

Morgan has spearheaded the development of many roadmaps at Bessemer, authoring notable reports such as Bessemer's 10 Laws of Healthcare and Six Imperatives for AI-first Companies.

Morgan is pursuing medical training at The Warren Alpert Medical School of Brown University with a research focus on artificial intelligence in biomedicine. His research has been published in leading academic journals including Nature Medicine, NEJM AI, and PLOS. Morgan is on the Editorial Team at NEJM AI and a Board Director at Coalition for Health AI. Prior to Bessemer, he worked in data science roles in healthcare technology. He earned his bachelor of science in Computational Decision Sciences from Brown University.

Portfolio Companies

Indicates Enduring